{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T06:30:02Z","timestamp":1792218602072,"version":"4.4.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T00:00:00Z","timestamp":1104537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2005,1]]},"DOI":"10.1016\/j.ejca.2004.10.006","type":"journal-article","created":{"date-parts":[[2004,12,16]],"date-time":"2004-12-16T00:10:09Z","timestamp":1103155809000},"page":"98-103","source":"Crossref","is-referenced-by-count":31,"title":["Vincristine pharmacokinetics and response to vincristine monotherapy in an up-front window study of the Dutch Childhood Leukaemia Study Group (DCLSG)"],"prefix":"10.1016","volume":"41","author":[{"given":"Ellis","family":"Groninger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiny","family":"Meeuwsen-de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Koopmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Uges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"Sluiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjo","family":"Veerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem","family":"Kamps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siebold","family":"de Graaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ejca.2004.10.006_bib1","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1046\/j.1365-2141.2000.01849.x","article-title":"The management of high-risk lymphoblastic leukaemia in children","volume":"108","author":"Chessells","year":"2000","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.ejca.2004.10.006_bib2","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/0304-3835(88)90294-7","article-title":"Adaptation of the rapid automated tetrazolium dye based (MTT) assay for chemosensitivity testing in childhood leukemia","volume":"41","author":"Pieters","year":"1988","journal-title":"Cancer Lett"},{"issue":"2","key":"10.1016\/j.ejca.2004.10.006_bib3","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/bjc.1989.44","article-title":"Comparison of the rapid automated MTT-assay with a dye exclusion assay for chemosensitivity testing in childhood leukaemia","volume":"59","author":"Pieters","year":"1989","journal-title":"Br J Cancer"},{"issue":"1-2","key":"10.1016\/j.ejca.2004.10.006_bib4","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays","volume":"65","author":"Mosmann","year":"1983","journal-title":"J Immunol Methods"},{"issue":"7","key":"10.1016\/j.ejca.2004.10.006_bib5","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1182\/blood.V90.7.2723","article-title":"In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia","volume":"90","author":"Kaspers","year":"1997","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ejca.2004.10.006_bib6","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/1097-0142(197102)27:2<247::AID-CNCR2820270202>3.0.CO;2-C","article-title":"Drug dosage and remission duration in childhood lymphocytic leukemia","volume":"27","author":"Pinkel","year":"1971","journal-title":"Cancer"},{"issue":"3 Suppl. 4","key":"10.1016\/j.ejca.2004.10.006_bib7","first-page":"15","article-title":"Individualized dosages of chemotherapy as a strategy to improve response for acute lymphocytic leukemia","volume":"28","author":"Evans","year":"1991","journal-title":"Semin Hematol"},{"issue":"2","key":"10.1016\/j.ejca.2004.10.006_bib8","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/BF00255486","article-title":"Can severe vincristine neurotoxicity be prevented?","volume":"8","author":"Desai","year":"1982","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ejca.2004.10.006_bib9","unstructured":"Gidding CE, Fock JM, Begeer JH, et al. Vincristine disposition and neurotoxicity in children. Abstract N22-2068-ASCO 1998. 16-5-1998"},{"key":"10.1016\/j.ejca.2004.10.006_bib10","first-page":"277","article-title":"Dose individualisation in cancer chemotherapy: pharmacokinetic and pharmacodynamic relationships","volume":"4","author":"van Warmerdam","year":"1995","journal-title":"Cancer Res Ther Cont"},{"issue":"8","key":"10.1016\/j.ejca.2004.10.006_bib11","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1056\/NEJM199802193380803","article-title":"Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia","volume":"338","author":"Evans","year":"1998","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejca.2004.10.006_bib12","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1365-2141.1981.tb02684.x","article-title":"The morphological classification of acute lymphoblastic leukaemia: concordance among observers and clinical correlations","volume":"47","author":"Bennett","year":"1981","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.ejca.2004.10.006_bib13","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2141.1976.tb03563.x","article-title":"Proposals for the classification of the acute leukaemias. French\u2013American\u2013British (FAB) co-operative group","volume":"33","author":"Bennett","year":"1976","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.ejca.2004.10.006_bib14","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0010-468X(79)90025-4","article-title":"A program package for simulation and parameter estimation in pharmacokinetic systems","volume":"9","author":"D\u2019Argenio","year":"1979","journal-title":"Comput Meth Prog Bio"},{"issue":"4","key":"10.1016\/j.ejca.2004.10.006_bib15","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/mpo.2950240405","article-title":"Vincristine disposition in children with acute lymphoblastic leukemia","volume":"24","author":"de Graaf","year":"1995","journal-title":"Med Pediatr Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2004.10.006_bib16","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1097\/00007691-200108000-00014","article-title":"An automated method for the bioanalysis of vincristine suitable for therapeutic drug monitoring and pharmacokinetic studies in young children","volume":"23","author":"Koopmans","year":"2001","journal-title":"Ther Drug Monit"},{"issue":"1\u20132","key":"10.1016\/j.ejca.2004.10.006_bib17","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0378-4347(91)80481-Q","article-title":"Sensitive method for the determination of vincristine in human serum by high-performance liquid chromatography after on-line column-extraction","volume":"572","author":"Bloemhof","year":"1991","journal-title":"J Chromatogr"},{"issue":"1","key":"10.1016\/j.ejca.2004.10.006_bib18","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1203\/00006450-200207000-00021","article-title":"Pharmacokinetics of vincristine monotherapy in childhood acute lymphoblastic leukemia","volume":"52","author":"Groninger","year":"2002","journal-title":"Pediatr Res"},{"issue":"6","key":"10.1016\/j.ejca.2004.10.006_bib19","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/BF01070904","article-title":"Optimal sampling times for pharmacokinetic experiments","volume":"9","author":"D\u2019Argenio","year":"1981","journal-title":"J Pharmacokinet Biopharm"},{"issue":"3","key":"10.1016\/j.ejca.2004.10.006_bib20","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s002800050968","article-title":"Vincristine pharmacokinetics after repetitive dosing in children","volume":"44","author":"Gidding","year":"1999","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1016\/j.ejca.2004.10.006_bib21","first-page":"241","article-title":"Pharmacology studies of 1-beta-d-arabinofuranosylcytosine in pediatric patients with leukemia and lymphoma after a biochemically optimal regimen of loading bolus plus continuous infusion of the drug","volume":"49","author":"Avramis","year":"1989","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.ejca.2004.10.006_bib22","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S0006-2952(97)00615-1","article-title":"Vincristine saturation of cellular binding sites and its cytotoxic activity in human lymphoblastic leukemia cells: mechanism of inoculum effect","volume":"55","author":"Kobayashi","year":"1998","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"10.1016\/j.ejca.2004.10.006_bib23","first-page":"1235","article-title":"Teniposide (VM26) disposition in children with leukemia","volume":"44","author":"Sinkule","year":"1984","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.ejca.2004.10.006_bib24","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1200\/JCO.2001.19.4.1040","article-title":"Improved response with higher corticosteroid dose in children with acute lymphoblastic leukemia","volume":"19","author":"Schwartz","year":"2001","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804904008226?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804904008226?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,4]],"date-time":"2020-04-04T19:21:17Z","timestamp":1586028077000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804904008226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,1]]}},"alternative-id":["S0959804904008226"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2004.10.006","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2005,1]]}}}